cells

human, bone marrow, leukemia, pre-B cell

Cell Type:

B cell

Tissue Origin:

blood

Species:

human

Research Area:

Cancer Research/Cell Biology

Immunotherapy / Hematology

Cell Characteristics:

Suspension

Transfection Information

Lonza Optimized Protocol
Optimization Guideline

Filter:

The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our optimization strategy to get further guidance on how to easily determine optimal Nucleofection conditions yourself.

Kit	Program	Cells	Efficiency	Viable Cells	Substrate		Format	Platform
R	T-020	3e6	43%	83%	Plasmid (general)	5 µg	100 µl	I/II/2b
R	T-027	3e6	47%	83%	Plasmid (general)	5 µg	100 µl	I/II/2b
R	T-016	3e6	55%	84%	Plasmid (general)	5 µg	100 µl	I/II/2b
L	X-001	5e6	46%	57%	Plasmid (general)	2 µg	100 µl	I/II/2b

Citations

Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter snp that alters PARP1 binding and SMARCB1 expression

Categories:

Transfection

Authors:

Pottier N, Cheok MH, Yang W, Assem M, Tracey L, Obenauer JC, Panetta JC, Relling MV, Evans WE

In:

Hum Mol Genet (2007) 16(19): 2261-71

Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity